TRMT112P6

Across TCGA pan-cancer cohorts, TRMT112P6 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated TRMT112P6 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TRMT112P6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRMT112P6 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SKCM show a favorable association.

LIHC, KICH, and UVM are the cancer types where TRMT112P6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Quartile	All	0.320	0.561	<.001	78	view →
KICH	DFS	Median	All	0.632	1.000	.001	43	view →
UVM	OS	Tertile	All	0.600	0.936	.004	41	view →
KIRC	DFS	Quartile	III,IV	0.578	0.328	.010	31	view →
LGG	DFS	Median	All	0.660	0.816	<.001	31	view →
SKCM	OS	Median	III,IV	0.790	0.618	.001	22	view →
OV	OS	Tertile	IV	0.857	0.691	.006	18	view →
LUAD	DFS	Tertile	All	0.703	0.850	.009	17	view →
BLCA	DFS	Tertile	All	0.687	0.511	.019	16	view →
ACC	DFS	Median	All	0.192	0.728	.004	15	view →
BRCA	DFS	Median	All	0.932	0.965	.002	13	view →
CESC	DFS	Tertile	III,IV	0.898	0.475	.008	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

TRMT112P6–LIHC (DFS)

Open the LIHC breakdown →